Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Placebo-controlled, Randomised, Observer-blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years

Next Previous
Search
Trial Profile

A Phase 2, Placebo-controlled, Randomised, Observer-blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 6425090 (Primary) ; Toxoids
  • Indications Clostridium difficile infections
  • Focus Adverse reactions
  • Acronyms toxoid-alone study
  • Sponsors Pfizer

    • Most Recent Events

    • 03 Sep 2021 Results assessing the safety and immunogenicity data from two clinical studies (QS-21 study NCT02052726 and toxoid-alone study NCT02117570) that evaluated the use of alternative formulations of this vaccine candidate in healthy adults, published in the Vaccine.
    • 05 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2015 Planned number of patients changed from 185 to 749 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top